Eyeing approval by the U.S. Food and Drug Administration, Research Triangle Park-based surgical robotics company TransEnterix (NYSE MKT: TRXC) has cracked the Japanese market, selling its first Senhance system there to the Saitama Medical University International Medical Center near Tokyo.
“While Senhance is currently not approved for sale in Japan, this placement falls under the Japanese physician import license which allows clinicians to purchase unapproved cutting-edge medical devices," analyst…
Eyeing approval by the U.S. Food and Drug Administration, Research Triangle Park-based surgical robotics company TransEnterix (NYSE MKT: TRXC) has cracked the Japanese market, selling its first Senhance system there to the Saitama Medical University International Medical Center near Tokyo.
“While Senhance is currently not approved for sale in Japan, this placement falls under the Japanese physician import license which allows clinicians to purchase unapproved cutting-edge medical devices," analyst…